

Acute coronary syndromes (ACS) committee meeting 10

Date: 16/7/2019

Location: RCP London

Minutes: Final

Committee members present:	
Margaret Lally (Chair)	Present for notes 1 – 8
Simon Corbett (Topic adviser)	Present for notes 1 – 8
Farrah Al-Ghita	Present for note 1 - 8
Chris Cassidy	Present for notes 1 – 8
Ewan Gittins	Present for notes 1 – 8
Lance Goodman	Present for note 1 – 8
Muhammad Murad Khan	Present for note 1 – 8
Alun Roebuck	Present for note 1 – 8
Jaydeep Sarma	Present for note 1 – 8
Alex Sharp	Present for note 1 – 8
Neil Swanson	Present for notes 5 - 8

In attendance:		
Rupert Franklin	Senior Guidelines Commissioning Manager, NICE	Present for notes 1 – 5
Ian Mather	Business Analyst, Resource Impact Assessment, NICE	Present for notes 1 – 8
Emma Cowles	Senior Health Economist, NGC	Present for notes 6 - 8
Annabelle Davies	Health Economist, NGC	Present for notes 1 – 8
Saoussen Ftouh	Senior Research Fellow, NGC	Present for notes 1 – 8
Bernard Higgins	Clinical Director & Guideline Lead, NGC	Present for notes 5 – 8
Sedina Lewis	Senior Research Fellow, NGC	Present for notes 1 – 8

Nancy Pursey	Senior Project Manager, NGC	Present for notes 1 – 8
--------------	--------------------------------	-------------------------

Apologies:	
Jill Cobb	Information Specialist, NGC
Agnes Cuyas	Information Specialist, NGC
Kate Lovibond	Health Economics Lead, NGC
Anna Sparshatt	Senior Digital Editor, NICE

1. Welcome and objectives for the meeting
<p>The Chair welcomed the Committee members and attendees to the 10th meeting on acute coronary syndromes.</p> <p>The Chair informed the Committee that apologies had been received. These are noted above.</p> <p>The Chair outlined the objectives of the meeting, which included:</p> <ul style="list-style-type: none"> • Presentation on NICE digital pathways • Review the clinical and cost effectiveness evidence for combinations of antiplatelet and anticoagulant therapies for people who have had an ACS and a separate indication for anticoagulation • Discuss and agree inputs for the economic model on dual antiplatelet therapy • Review results of re-run literature searches and finalise recommendations for three topics (stents, early invasive vs. conservative management, bivalirudin)
2. Confirmation of matter under discussion, and declarations of interest
<p>The Chair confirmed that, for the purpose of managing conflicts of interest, the matters under discussion were combinations of antiplatelet and anticoagulants, dual antiplatelet therapy, stents, bivalirudin and early angiography.</p> <p>The Chair asked everyone to verbally declare any interests that have arisen since the last meeting. No new interests were declared.</p> <p>The Chair and Guideline Lead (ML and BH) reviewed the register of previously declared interests prior to the meeting. Two committee members had previously declared interests relating to Abbott, a manufacturer of stents. CC attended a</p>

conference on left ventricular assist devices (LVAD) in June 2019 hosted by Abbott. Only attendance, standard travel and accommodation costs were covered and there was no additional hospitality. The agreed action was to declare and participate in discussions on stents.

JS attended the complete revascularisation meeting hosted by Abbott in March 2018. JS did not participate in stents discussion at February committee meeting as he did not attend the meeting. On further review of his conference attendance, it was confirmed that JS only accepted attendance, standard travel and accommodation and no additional hospitality was accepted. Therefore the agreed action was to declare and participate in discussions on stents. The Chair confirmed that both CC and JS can join in the discussions of stents at today's meeting. NP will update the declarations of interest register.

The Chair confirmed that the interests declared did not prevent the attendees from fully participating in the meeting.

3. Minutes of last meeting

The Chair asked the Committee if it wanted any changes made to the minutes of the last meeting. The Committee agreed that the minutes were a true and accurate account of the meeting.

4. Presentation: NICE Pathways

RF gave a brief overview of NICE Pathways in AS's absence. Committee members were invited to volunteer to review the draft pathway. NP will liaise with AS as regards volunteers and next steps for the Pathways work.

5. Evidence review: combination of antiplatelet and anticoagulant

The Chair introduced SF and AF who gave a presentation on the evidence for the clinical and cost effectiveness for the review question: What is the most clinically and cost effective combination of antiplatelet and anticoagulant therapies for people who have had an ACS and a separate indication for anticoagulation? The committee discussed the evidence and drafted recommendations.

6. Presentation: dual antiplatelet therapy economic model inputs

The Chair introduced AD, who gave a presentation on the inputs for the dual antiplatelet therapy economic model.

7. Presentation: re-run literature searches

The Chair introduced SF, SL and AD who presented evidence reviews for three topics that had been updated following re-run literature searches. The topics were

stents, bivalirudin and early angiography.
--

8. Any other business

None,

Date of next meeting: 19/09/2019

Location of next meeting: Holiday Inn Regent's Park, Carburton Street, London